150521-32-7

Basic information

• Product Name: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2S-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-PIPERIDINECARBOXYLIC ACID, 2-FORMYL-,1,1-DIMETHYLETHYL ESTER(S);(S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(S)-1-Boc-2-piperidinecarboxaldehyde;(S)-2-Formyl-1-piperidinecarboxylic acid tert-butyl ester;(S)-tert-butyl 2-formylpiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 2-formyl-, 1,1-dimethylethyl ester, (2S)-;(2S)-2-Formylpiperidine, N-BOC protected
• CAS NO: 150521-32-7
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.27
• Mol File: 150521-32-7.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 295.431 °C at 760 mmHg
• Flash Point: 132.472 °C
• Appearance: /
• Density: 1.115 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.97±0.40(Predicted)
• CAS DataBase Reference: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(150521-32-7)
• EPA Substance Registry System: (S)-2-FORMYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(150521-32-7)

Safety Data

• Hazardous Substances Data: 150521-32-7(Hazardous Substances Data)

Usage

General Description

"(S)-2-Formyl-piperidine-1-carboxylic Acid Tert-Butyl Ester" is an organic compound that contains several functional groups, including the piperidine ring, carboxyl group, and ester group. It exists as a single stereoisomer due to the presence of a chiral center (indicated by the (S) configuration), which gives this molecule unique stereochemical properties. The piperidine ring contributes to its basicity, the ester group makes it prone to hydrolysis and the formyl group provides aldehyde functionality. It is often used as an intermediate in the synthesis of other chemicals, particularly in pharmaceutical and agrochemical industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 35677-83-9 methyl (S)-pipecolinate 
• 41373-39-1 (S)-pipecolinol 
• 200184-53-8 (S)-1-tert-butyl 2-methyl piperidine-1,2-dicarboxylate 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 68-12-2 N,N-dimethyl-formamide 
• 3433-37-2 piperidin-2-ylmethanol 
• 157634-00-9 tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate 
• 259133-67-0 2-carboxy-N-Boc-1,4,5,6-tetrahydropyridine 
• 146337-23-7 tert-butyl 3-methoxypiperidine-1-carboxylate 
• 85908-96-9 2-oxopiperidine-1-carboxylic acid tert-butyl ester 
• 86953-81-3 tert-butyl 2-hydroxypiperidine-1-carboxylate 
• 131667-57-7 tert-butyl 1,2,3,4-tetrahydro-1-pyridinecarboxylate 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 

Downstream Products

• 1214914-34-7 (S)-2-(2-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 68682-28-0 (2,8-bis-trifluoromethyl-quinolin-4-yl)-piperidin-2-yl-methanol; hydrochloride 
• 393827-07-1 (S)-2-vinyl-piperidine-1-carboxylic acid tert-butyl ester 
• 134441-93-3 tert-butyl (2S)-2-(hydroxymethyl)piperidine-1-carboxylate 
• 639458-43-8 (S)-2-(2-oxo-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1094503-74-8 tert-butyl (2S)-2-{[3-(ethoxycarbonyl)phenyl](hydroxy)methyl}piperidine-1-carboxylate 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.